TrialOncotarget2016

Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects.

Xiaoliang Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.